C-KFAJAruna Bio
neural exosomes, blood-brain barrier, neuroregeneration
deliverydeliveringextracellular vesicle
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KFAJ
C-KFAJC-KFAJneural exosomes, blood-brain barrier, neuroregeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Exosome Diagnostics & Therapeutics Market Growth Report 2032 --> Download PDF Industries Semiconductor & Electronics Information And Communication Technology Healthcare Food And Beverages Equipment And Machinery Chemicals And Materials Automotive Aerospace And Defense Energy & Power Packaging, Construction and Manufacturing Consumer Goods Future Trends Offering Infographics --> Media Center Blogs Press Release Video Success Stories Contact Us --> About--> --> Contact Us --> --> Login Login Home Reports Healthcare Exosome Diagnostics And Therapeutics Market Exosome Diagnostics And Therapeut … s & Reagents), Source (Stem Cells, Blood & Blood Plasma, Urine, Other Sources), Application (Cancer, Dermatological Diseases, Musculoskeletal Disorders, Cardiovascular Diseases, Other Application), End User (Hospitals, Clinics and Physician Settings) and Region. November 2025 --> Last Updated: November 7, 2025 | Report Code: SNS/HC/4879 | Page 355 Download PDF Buy Now Exosome Diagnostics And Therapeutics Market Download PDF Buy now Description Table of content Segmentation Me … y Source (Stem Cells, Blood & Blood Plasma, Urine, Other Sources) • By Application (Cancer, Dermatological Diseases, Musculoskeletal Disorders, Cardiovascular Diseases, Other Applications) • By End User (Hospitals, Clinics and Physician Settings) Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe [Germany, France, UK, Italy, Spain, Netherlands, Switz
Georgia Research Alliance MENU Who We Are Trustees GRA Staff Senior Advisors Supporters Recruiting Talent Eminent Scholars Distinguished Investigators Senior Fellows Enhancing Labs Sharing Core Facilities Growing Companies Grants & Loans How to Apply Portfolio Greater Yield Initiative GRA Venture Fund Newsroom Features Blog GRA Notes Newsletter Publications Other GRA Initiatives Solve Sickle Cell Workforce Development DONATE GRA Notes - Archives May, 2026 Georgia Southern, Kennesaw State become newest members of GRA Micron Biomedical opens manufacturing facility in Georgia Farming, optimized: … ) GRA Distinguished Investigator Lance Wells receives Michael J. Fox Foundation grant for Parkinson’s research Codoxo featured on GRA.org Thanks to: Global real estate company CBRE Read more > February, 2026 Grant to Marcus Autism Center will fund exploration of autism severity Grant to Marcus Autism Center will fund exploration of autism severity Investors show high confidence in Altesa BioSciences with $75 million Series B funding round Mercer helps bring EarliPoin … orators discover enzymes that could yield new medicine compounds FDA clears IND application from Moonlight Therapeutics EMCOOL’s Everest chip promises next-level heat reduction Tommy Holder receives Four Pillars Tribute Award To Market: A drug that promotes safe weight loss by burning fat and capsules that make vaccines and therapies easier to transport and store Thanks to: W.C. Bradley Co. Read more > September, 2025 Governor and First Lady highlight 35th anniversar … by Eminent Scholar Vince Calhoun secures grants for cutting-edge brain projects Grant to Eminent Scholar Rampi Ramprasad will advance design of new sustainable packaging materials To Market: Channel Therapeutics (Mercer) and a new 3D-printed aircraft joint (Georgia Southern) Thanks to: Synovus Bank Read more > July, 2025 Tribute: In GRA, Tom Cousins saw Georgias universities as key to future growth Tribute: In GRA, Tom Cousins saw Georgias universities as key to future gro … rvous system disorders GRA Eminent Scholar Bill Koros to receive Monie A. Ferst Award Weeders on the way: Ground Control Robotics creates weeding robots GRA Trustee Emeritus Tommy Holder to receive Four Pillar Tribute and Award Our Thanks: To the Georgia Power Foundation Read more > April, 2025 GRA-backed Pindrop reaches major milestone: $100
Financings for April 14, 2021 | 2021-04-14 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes a
Vicarious Surgical Names Healthcare Veteran Stephen From as New CEO | RBOT Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cr … ange Listed Company Manual Rule 303A.08 (the “Inducement Rule”), a stock option award to be made to Mr. From as a material inducement to his entering into employment with the Company. The stock option award was approved by the Company’s Board and by its Compensation Committee with a grant date of August 7, 2025. The stock option to be granted to Mr. From will be exercisable for up to 297,600 shares of the Company’s Class A common stock, will have an exercise price equal to th … ise price equal to the closing price of the Class A common stock on the date of grant, and will expire on the ten-year anniversary of the grant date. One-quarter of the stock options will vest and become exercisable on the one-year anniversary of the grant date, and the remainder of the stock options will vest in thirty-six equal consecutive, equal monthly installments thereafter, subject to Mr. From’s continued service to the Company through each vesting date and subject to … e and subject to accelerated vesting in certain circumstances. The stock option award will be made outside of the Company’s existing 2021 Equity Incentive Plan, as amended (the “Plan”), but will be subject to terms and conditions generally consistent with those in the Plan, other than with respect to such terms and conditions intended to comply with the Inducement Rule. About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company
Eshelman Ventures | Wilmington Venture Capital | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home Venture Capital Eshelman Ventures Venture Capital Updated: Jun 3, 2026 Eshelman Ventures Local firm working w/ private healthcare company investments including startups, private equity funds & more. See Investment Criteria and View Portfolio. Eshelman Ventures Local firm working w/ private healthcare company investments including startups, private equity funds & more. See Investment Criteria and View Portfolio. Website www.eshelmanventures.com LinkedIn linkedin. … ustry and academic research institutions. Does Eshelman Ventures participate in fund commitments or only direct deals? The firm states it invests through multiple channels: angel investing in startups, co-investing alongside venture capital funds, committing to private equity funds on the primary and secondary markets, backing academic spinouts, and allocating to hedge funds. It does not publish the ratio of direct to fund commitments. What investment stages does Eshelman Ven … Preqin Altss vs PitchBook Altss vs FINTRX Altss vs Dakota Company About us Why Submit Data How we Collect Data Press Careers Contribute Submit your firm Submit a deal Submit a fund
Aruna Bio, Inc. News and Press Releases | PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 1 --> 1 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected. Items per page: 25 per page 50 per page 75 per page 100 per page Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 AM - 9 PM ET Chat with an Expert Contact Us … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
August 2019 Innovation Gateway Highlights Skip to the content University of Georgia Directory Forms & Policies Calendar Research News Donate Now Apply --> --> Search Submit Menu MENU MENU IP & Licensing Commercialization Process Material Transfer Requests & Confidential Disclosure Requests New Inventor Form Disclose New Invention Guide to IP and Commercialization Resources Meet the Team – IP and Licensing Startups Commercialization Process FAST Grant UGA Startup Portfolio Conflicts of Interest Startup Facilities Resources Meet the Startup Team For Industry Available Technologies Av … ources Meet the Team – IP and Licensing Startups Commercialization Process FAST Grant UGA Startup Portfolio Conflicts of Interest Startup Facilities Resources Meet the Startup Team For Industry Available Technologies Available Artwork and Digital Images Industry Express Licensing Industry Collaboration Pathways Resources for Industry Programs Innovation Bootcamp UGA I-Corps M.A.P.S. Startup 101 Georgia Startup License UGA NAI Chapter | National Academy of Inventors Impact Pro … nistrator to manage our day-to-day IP administration activities. Learn more and apply here! Do you have an idea for a new technology or product? Innovation Gateway is currently accepting applications for its Fall 2019 NSF I-Corps cohort. Learn more and apply here! Are you interested in entrepreneurship and startup companies? Innovation Gateway is seeking university and community members to help faculty and researchers move their I-Corps projects forward through customer disco … your concept can develop from an idea into a scalable business. Learn more and apply here! Innovation Gateway hosted the SEC Technology Transfer Directors meeting in Atlanta. UGA has hosted this meeting for the past eight years as a forum to discuss technology commercialization best practices among SEC universities. ← August 2019 Spotlighted Entrepreneur – Hang Yin → Check Out Our New Commercialization Guide! CONTACT General Inquiries 706-542-1404 Main Office 110 T
AMD Ventures invests in Somite AI for cell therapy | Micha Y. Breakstone posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
%PDF-1.7 %���� 1 0 obj >/Metadata 8476 0 R/ViewerPreferences 8477 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.2 840.96] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��ZMo�8����^�4�?��@�t�-P���Cу�qSI�u����Ĵ)Z"��`)��z3��8$={�ݭ�.�;�����n�X~[]�ϳ����l��~5���^�-v����ӏ�w���jq�ھxA^]^��#F�9g Yr� z&������x�yB�_���x�z�s �q��� I��% ִД�ID �� ��ח(4u��� fK%���K���*�$�m���x�^PmB��%� ) ;��C-k�������i�����R�@\�JV �^R?�� �p %�E���W��4=C�������P�����C��_�Q�� $60�Na��_� ⃡�h+��� �H
GRA Venture Fund, LLC try{Typekit.load({ async: true });}catch(e){} Toggle navigation MENU × Close About Leadership How We Invest Portfolio Companies FAQs Contact Us A vote of confidence in select ventures Companies receiving early-stage investment from GRA Venture Fund, LLC have demonstrated extraordinary potential. The following companies in our portfolio have met the criteria of the Fund's investors: ABE is a globally compliant securities exchange that connects companies to billions of investors around the world — at a fraction of the cost. By combining the safety of a stock ex … rted by public and private sources including Dynamk Capital and the GRA Venture Fund. Lucid Scientific website » Micron develops pharmaceutical products, based on its microneedle patch technology , that are designed to provide enhanced protective (vaccine) and therapeutic (drugs) effects and superior patient compliance. The company’s microneedle products simplify and administration, distribution and storage logistics. Micron Biomedical website » Nyra Medical … p; | 404.332.9770 Privacy | Georgia Research Alliance © GRA Venture Fund, LLC | All Rights Reserved
Diagnostic Exosome Biomarkers Market | Global Market Analysis Report - 2036 MENU --> Search Industry Automotive Consumer Product Food & Beverage Chemicals and Materials Healthcare Travel & Tourism Process Automation Technology Industrial Automation Services & Utilities Oil & Gas Packaging Testing Equipment Industries at a Glance About About Us Careers Why FMI Become a Client Client Testimonials Services Syndicated Research Customized Research Investment Research Social Media Research Insights --> Market Reports Methodology Custom Research Media Event Articles Blog Thought Leadership Authors Co … ers Market is segmented by Product Type (Diagnostic Exosome Biomarkers Market), Application (Oncology, Neurodegenerative Disorders, Metabolic Disorders, Others), End User (Cancer Institute, Hospital, Diagnostic Center, Others), and Region. Forecast for 2026 to 2036. --> Key Takeaways, Market Size, and Forecast 2025 Market Size: USD 266.10 million 2036 Market Size: USD 1348.85 million Forecast CAGR: 15.9% from 2026 to 2036 Incremental Opportunity (2026–2036): USD 1040.44 … commercial and industrial buyers. Oncology is likely to hold 53.7% share in the application segment, reflecting established application requirements. Geography and Competitive Outlook India is likely to remain a key market at 19.88% CAGR, reflecting the scale of domestic demand and investment in capacity expansion. USA is likely to sustain growth at 16.2% CAGR on account of regulatory compliance requirements and end-use sector modernization. Companies that can combine cost co … lopments, sustainability mandates, and cost-performance optimization across key application segments. Demand is further supported by replacement cycles in mature markets and capacity expansion in high-growth regions. Companies that can improve cost competitiveness while delivering consistent performance across primary applications are likely to strengthen their position over the forecast period. Diagnostic Exosome Biomarkers Market Definition The diagnostic exosome biomarkers … iomarkers market encompasses products and solutions classified by product type, application, end user, technology, sample type, workflow stage. The market scope covers commercially traded products across the full value chain, from production and processing through distribution and end-use application. Diagnostic Exosome Biomarkers Market Inclusio
Speakers - UGA Graduate School University of Georgia Apply Now Give Search Menu Graduate Programs Prospective Students Current Students Faculty & Staff Home > Academic & Professional Development > Professional Resources > Career Exploration > Academic-Specific Career Fairs > Life Sciences Career Day 2023 > Speakers Speakers The UGA Life Sciences Career Day professional development conference combines speakers, panels, small-group sessions and interactive workshops featuring professionals from industry, government and non-profit organizations. Read more about the spe … n’s primary role is to lead the institute’s sponsored programs office, managing grant administration from proposal to close-out. Flo advanced into this role after changing career paths at HudsonAlpha from senior scientist to research administrator. She is passionate about serving in a leadership role at this Huntsville, AL non-profit, whose mission is to use genomics to improve the human condition. Flo is a California transplant to Alabama, a graduate of Stanford University a … le accomplishments such as being awarded the division- wide teaching innovation award, being a Special Collections Faculty Fellow, and being a part of the Active Learning Summer Institute. Linkedin Karen Burg, PhD Welcome & Event Intro Vice President for Research UGA Provost's Office Burg was named Vice President for Research in 2021. She holds the Harbor Lights Chair in Small Animal Studies in the College of Veterinary Medicine and previously served as Vice President for … to a vast array of medical technologies. Dr. Goodwin completed a post-doctoral fellowship in the Harvard-MIT Health Sciences and Technology program. She holds a Ph.D. in Biomedical Engineering from Stony Brook University. Linkedin Hunter Johnson Breakout Session: Uncle Sam Wants You Deputy Director US Environmental Protection Agency, Region 4, Laboratory Services & Applied Science Division Hunter Johnson is the Deputy Director, Laboratory Services and Applied Science Div … Cancer Institute (NCI) Technology Transfer Center. In this unique post-doctoral fellowship, Emily facilitates the commercial development of NCI innovations by initiating collaborations with and licensing to industry partners. Her work integrates alliance development, technology assessment, targeted marketing, and science communication to market a
ArunA Bio Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech stack Mark
citybuzz : Atlanta : Venture Capital Atlanta Search Share Your News Venture Capital Posted on 8/26/19 Innovative Ware Care Appoints Robert P. Baird Jr., CEO Innovative Water Care LLC, a leading provider of residential and industrial water solutions, announced today the appointment of Robert P. Baird, Jr. as Chief Executive Officer.Platinum . . . Posted on 8/22/19 Meridian Acquires Epoxies Etc Meridian Adhesives Group announced today the acquisition of Epoxies, Etc., a leading resin formulator of Posted on 8/22/19 Virtua Partners Acquires North Carolina Hotel Under Construction SCOTTSDALE, Ariz … ted on 7/25/19 Ciox Secures $30M Investment From Merck Global Health Innovation Fund Ciox Health, the nation’s leader in clinical data exchange, today announced a $30 million equity investment to enhance its core capability of providing clinical data Posted on 7/25/19 Sandata Secures Significant Growth Equity Investment from Accel-KKR Sandata Technologies, LLC, the leading provider of Electronic Visit Verification ("EVV") and home health technology solutions, today
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Barry L. Storey Director (since 2016) Barry L. Storey is the Principal of BLS Holdings Group, LLC, an Augusta, Georgia-based company with the primary focus of managing a portfolio of retail real estate properties and various alternative assets. Prior to January 2015, he was the Co-Founding Partner of Hull Storey Gibson Companies, LLC, a retail acquisition and development real e … opic and community service. In 2010 he received the “Outstanding Philanthropist Award” from the Young Professionals of Augusta and in 2014 he was inducted into the Central Savannah River Area Business Hall of Fame. He is Past President of the Exchange Club of Augusta, Past President of the Family Y Board of Directors and Past Chairman of the Episcopal Day School Board of Trustees. Return to Board of Directors Contact us to discover more CONTACT US Financial Conflict of Intere
%PDF-1.7 %���� 1 0 obj >/Metadata 1778 0 R/ViewerPreferences 1779 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 20 0 R 29 0 R] /MediaBox[ 0 0 841.92 595.32] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]�r Ǒ}g�a" ��8�fW�[v8� )[%kh��� @`� ``@Q������}ؼT�-���ݰÄ0�� �ԇ��M����Q���$�q��O�!�����oޮV��C#���W�V�4�MW��?\�����j�hߞ��f��@S*���w�0V��X��/��)t�qr���r� ==��������f�� U� ^�����Ͳ�iZFi�@^�)S,�Z�hp�����iaؼ�����Eeʁ������-���}��E�� p�A�e���9�� 7gכ��uyt�y����X�G�+����0���dz�n Uί`:���[�{��eZ���T3�ͼj�� �
AR Member, Author at Irrus Investments Skip to content Contact Us Rss Search for: HOME ABOUT ENTREPRENEURS ANGELS PORTFOLIO NEWS CONTACT US PORTAL Meeting Agendas Investee Companies Applications Newsletters View Profile Logout HOME ABOUT ENTREPRENEURS ANGELS PORTFOLIO NEWS CONTACT US PORTAL Meeting Agendas Investee Companies Applications Newsletters View Profile Logout gf7ugjgh About AR Member This author has not yet filled in any details. So far AR Member has created 12 blog entries. Bluedrop Medical raises €10.5m in funding 2023-07-04T15:20:12+01:00 Company will also create 25 jobs this year … eneurs Angels/Investors Case Studies Privacy Policy Cookies Policy Applications Apply for Membership Application for Investment © 2018 Irrus Investments | All Rights Reserved | [email protected] | Developed by STORM Web Rss Page load link Go to Top
Aruna to initiate clinical trial of AB126 for acute ischemic stroke Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product … Drug Administration (FDA) cleared the company’s investigational new drug (IND) application of its lead programme AB126. Go deeper with GlobalData Reports LOA and PTSR Model - AB-002 in Thrombosis Reports LOA and PTSR Model - Abelacimab in Ischemic Stroke Go deeper with GlobalData The gold standard of business intelligence. Find out more Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Mike Ryan Director (since 2022) Starting in 2005, Mike was a founder investor and board member of SedanaMedical, which was listed on the (NASDAQ) First North stock exchange in June 2017. He also served as the CEO of Sedana Medical from 2011 to 2017. The market capitalization of this company briefly exceeded $1 billion in 2020. Mr. Ryan was also the main shareholder and CEO of A
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Darren W. DeVore Director (since 2015) Darren W. DeVore serves as Managing Partner of Broad Pine Investments, a holding company for various private equity and venture capital activities. Broad Pine maintains investments in several businesses, including North Cape Investments, LLC, a private equity real estate business focused on the acquisition and management of skilled nursing
Aruna Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Healthcare Life Sciences & MedTech Summit Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Rele … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account March 31, 2025 16:05 ET | Source: Aruna Bio Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows BOSTON and ATHENS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions,
Aruna Bio - Our Progress Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Life-changing science What’s the potential of Aruna Bio’s research? What’s the potential of Aruna Bio’s research? Quite simply, our unique and proprietary neural-derived exosomes will present those treating neurodegenerative diseases with a transformational platform. Until now, the potential of exosomes in neurological science has not been fully explored. However
Aruna Bio - Our Pipeline Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Life-changing possibilities From concept to reality As the second leading cause of death worldwide, stroke represents a high unmet medical need. One in three people still die from a stroke, and a further one in three are left with a permanent disability. As proof of concept, AB126 has demonstrated activity in multiple blinded studies across various pre-clinical m
ArunA Bio Raises $13 Million in Common Stock Financing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases A … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals ArunA Bio Raises $13 Million in Common Stock Financing July 24, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Financing proceeds to advance ArunA Bio’s neural exosome therapies for neurodegenerative diseases and partnering activities July 24, 2019 11:00 UTC Financing proceeds to advanc … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankruptcy Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy June 23, 2026 · 3 min read · Gabrie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aruna Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Aruna Bio, Inc. Holding Company | 2003 | Georgia, United States | < 10 | www.arunabio.com Holding Company | 2003 | Georgia, United States | < 10 | www.arunabio.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Endocrinology and Metabolic Disease Exosomes mRNA siRNA Disease domain score A glimpse into the focused … u Hybridization (CISH), and Others In Situ Hybridization Market Segmentation By Application: Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others In Situ Hybridization Market Segmentation By End-User: Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others In Situ Hybridization Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces … day announced that the U.S. Patent and Trademark Office has allowed U.S. Patent Application No. 17/238760, entitled Neural Cell Extracellular Vesicles, with method of use claims pertaining to its lead program, AB126, for the treatment of neuro-inflammatory diseases. AB126 is an exosome derived from proprietary neural stem cells and has been shown to reduce inflammation in the brain. This patent contains broad claims for the method of using AB126 to treat multiple indications … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126 - Irrus Investments Skip to content Contact Us Rss Search for: HOME ABOUT ENTREPRENEURS ANGELS PORTFOLIO NEWS CONTACT US PORTAL Meeting Agendas Investee Companies Applications Newsletters View Profile Logout HOME ABOUT ENTREPRENEURS ANGELS PORTFOLIO NEWS CONTACT US PORTAL Meeting Agendas Investee Companies Applications Newsletters View Profile Logout Aruna Bio Announces FDA Clearance of IND for Lead Program AB126 Aruna Bio Announces FDA Clearance of IND for Lead Program AB126 Aruna Bio Announces FDA Clearance of IND for Lead Progr … eneurs Angels/Investors Case Studies Privacy Policy Cookies Policy Applications Apply for Membership Application for Investment © 2018 Irrus Investments | All Rights Reserved | [email protected] | Developed by STORM Web Rss Page load link Go to Top
Aruna Bio - Intro to AB126 Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Life-changing science What’s the potential of Aruna Bio’s research? For over 17 years, Aruna Bio has been leading the research and manufacturing of human neural stem cells in collaboration with some of the world’s leading research organizations. Today, we are advancing a new class of cell-free biologics – neural exosomes derived from neural stem cells. Our prop
WARF Startup Portfolio | Madison Wisconsin Inventions Wisconsin Alumni Research Foundation Careers Contact News & Media Main Navigation WARF Twitter Linked In YouTube Facebook Search Submit Search MENU MENU Invent Patenting Process Patenting FAQs Data Licensing Meet Our IP Experts Disclose your invention Warf Accelerator Warf Therapeutics Warf Ventures Commercialize Sign up for tech alerts Technologies Meet UW Inventors Starting a Company Licensing FAQs Warf Accelerator Warf Therapeutics Warf Ventures Programs & Events Warf Accelerator Warf Therapeutics Warf Ventures Watch Videos Ess … adors About WARF Warf Accelerator Warf Therapeutics Warf Ventures See $161.81 M grant to UW Contact Us Impact on UW-Madison Get Involved with WARF Success Stories WARF@100 Legacy Impact Future Startup Portfolio Startup Portfolio WARF Startup Portfolio Stats WARF holds equity in more than 30 of these companies , and more than 50 are located in Wisconsin. Some of these companies have achieved IPO status as publicly traded companies and have been acquired by large, well-establis
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact John Mangan, Jr Director (since 2016) John F. Mangan, Jr. has been active in the U.S. money management and securities industry for over 35 years. He is currently the CEO of JFM Capital, a Charlotte NC based private investment firm with interests in the capital markets and in several private businesses. From 1999 to 2007, Mangan was founder/CEO/CIO of Mangan McColl Partners, LLC … meritus board member of the North Carolina Tennis Foundation and the Children’s Scholarship Fund-Charlotte. Return to Board of Directors Contact us to discover more CONTACT US Financial Conflict of Interest in Research Policy Privacy Terms & Conditions Copyright © 2024 Aruna Bio, Inc. All rights reserved.
ArunA Bio Appoints Dr. Mark Sirgo as Chief Executive Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rele … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ArunA Bio Appoints Dr. Mark Sirgo as Chief Executive Officer January 15, 2019 | 3 min read Twitter LinkedIn Facebook Email Print Dr. Steven Stice to Continue Leading Company’s Research and Manufacturing Operations ATHENS, Ga.--( BUSINESS WIRE )-- ArunA Bio , a leader in the development of exo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Arunabio - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corp … ed States Stage Series B Total Funding $33.1M in 20 rounds Latest Funding Round Grant (prize money), Aug 07, 2025 , $***** Investors Eshelman Ventures & 7 more Ranked 16 th among 208 active competitors Employee Count 29 as on May 31, 2026 Similar Companies BioLife Solutions & 257 more View Arunabio's full profile Legal entities associated with Arunabio Arunabio is associated with 2 legal entit ies given below: Legal Entity Name Date of Incorporation Revenue Lates … ised a total funding of $33.1M over 20 round s . Its latest funding round was a Grant (prize money) round on Aug 07, 2025 for $ ***** . 1 investor participated in its latest round. Arunabio has 8 institutional investor s . Here is the list of recent funding rounds of Arunabio : Filter this list Date of Funding Funding Amount Round Name Post-Money Valuation Revenue Multiple Lead Investors Other Investors Aug 07, 2025 5576631 Grant (prize money) 1855392 7889473 8255357 2812691 … 576631 Grant (prize money) 1855392 7889473 8255357 2812691 Jun 01, 2022 1206597 Grant (prize money) 7777912 6442461 8839370 HHS Apr 14, 2021 8385414 Series B 2459465 4893176 6432331 2398647 Access funding benchmarks and valuations. Sign up today! View details of Arunabio 's funding rounds and investors Arunabio's founders and board of directors Founder? Claim Profile The founders of Arunabio is Steven Stice . Here are the details of Arunabio's key team members: … s 20 funding rounds to date. The company's 1st funding round was a $ ***** Grant (prize money) round . Where does Arunabio rank among its competitors? Arunabio ranks 16th amongst 208 active competitors , of which 36 are funded. It stands 4 th in terms of total funding among its competitors. The most recent competitors to raise funding was Bi
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact C. William "Bill" Griffin Chairman of the Board Bill Griffin is Executive Vice President and Senior Managing Director of Fidelity National Financial. In this role, Bill helps lead Fidelity’s efforts to deliver its end-to-end solutions to the country’s largest financial institutions. Because of his leadership in and knowledge of the mortgage industry, Bill has served o … ding for the new Terry College facilities. He received the Distinguished Alumni Award from the Terry College in 2007. Bill served on the Board of Trustees of the University of Georgia Foundation from 2007-2017. Additionally, Bill is Chairman of the Board of Aruna Biomedical, a bio tech company based in Athens. In Pittsburgh, he served on the Board of Governors of Oakmont Country Club (2003–2011) and was President (2004–2010) when Oakmont hosted the 2007 United States Open Cha
Aruna Bio - News Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Aruna in the news 8/19/2024 GLOBE NEWSWIRE: Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain 6/11/2024 FORCE WEBINAR: LifeSci Advisors Corey Davis and Stephen From Fireside Chat-May 2024 4/17/2024 FORCE WEBINAR: Dr. Sean Savitz, MD and Stephen From Fireside Chat -April 2024 3/11/2024 BIOSPACE: Exos
Aruna Bio secures US patent for exosome-derived neuroinflammation treatment Close Ask Healio AI New! News News CME CME Clinical Guidance Clinical Guidance Community Community Healio AI Healio AI AI Healio AI Mobile Account Account Anonymous User Log In Log In Log Out Log Out News News CME CME Clinical Guidance Clinical Guidance Community Community Healio AI Healio AI AI Healio AI Mobile Specialties Choose a specialty All Specialties Allergy/Asthma Cardiology Dermatology Endocrinology Gastroenterology Hematology/Oncology Hepatology Infectious Disease Nephrology Neurology Ophthalmology Optometry … ep it going! View Recommended CME Edit Goal Close Reminder from Healio CME Your deadline is here. You need {credits} Credits to reach your goal. View Recommended CME View goal Would you like to receive email reminders to complete your saved activities from Healio CME? Yes No Activity saved! You'll receive reminders to complete your saved activities from Healio CME. Unsubscribe Confirm your account You're logged in as . Please review your account details and complete any missi
Stice Lab UGA - Stice News / Research Search this site Embedded Files Skip to main content Skip to navigation Stice Lab UGA Home About Steven Stice Stice CV Stice Students / Alumni Stice News / Research Publications Partners Aruna Biomedical UGA Regenerative Bioscience Ctr. Openings in the Stice Lab Stice Lab UGA Stice News Steven Stice AIMBE awards 2025. Stice named AIMBE Fellow “I’m truly honored to be elected to AIMBE and to be recognized alongside so many incredible leaders in medical and biological engineering,” Stice said. “This isn’t just about me—it’s a reflection of the amazing teams … imal models into a pre-clinical human therapeutic. Aruna Bio is now on track to submit an Investigational New Drug with the FDA and initiate stroke patient clinical trials fall-2023. We expect this treatment to change the life of many Americans, especially in the “stroke belt” of the Southeast, where someone dies of a stroke every 40 seconds. Stice was honored to receive the Georgia Bio Innovation Award, for what was deemed as “success in translating science into useful produ
%PDF-1.7 %���� 4 0 obj >] /Length 231615 >> stream x��uT\]�/��@��!���NA >���{Hzy!!���CC��qA� ��=TTĻ���T�{����U_��9��~�O����Xm���)��!)9#3 + �����ȳ��2�r� ��Z�:�z�f�o,,���]\��= ���/em��j'�&N��$ |����T��f�5��oi����U�9 � r�5�}�.l�m2R ,�!PNqڻ�j���R��3QPN܃?�$p��eG��I�@�kɹ��RdA���SE0y�͇L� ?�1��^ �x��"�L)�t�~:$ü�X9C��M_8�� ����6u��9ʾ>+Ir��] 9~>���*�sJȳg�Ĺg��>����t��=OM�$z_Fz��9w>{���N [�$���kh�����'L�0�8Zj�o��h��O��xB)k7^zS1o�ǔ�� ��SR|&s?���6�e�$N8K����u��0�za� ����������O�K��� �{����?��d��*��kQiDA|��GePcp�s3s��.#�piB��(�;�ѯ�f�b … x�SL�\[��� ��ﴌܗ�b �9"�{!��\ Ӥ�9"�A�&�I����V��gE� )rt � �Df�o��f�Y�|kpEޏrFp"��Yq�>�;����?�{b�ޅ�6,�J��-�I8{T�K!g� 'u:���#c�.��Y����Y��Փe�j ,~6��g�oc��N���v��v �I�ei�r����$�`+���Q>�'��������O��7U��� � ݁���7� �ņ�O ����D̔�����_�߾��ѻl���4u?A�r��Y��p�s��� ��������&=�_5-Ё������ �Q�2-p'M�L}����y������*Jաh:r`��٢џz����j$骚[�SB� �ٽ�@O�E���R�eѴj�� �Ebv XY[(8e�4`���R9��$�f �^f��ՖZ��2��龚|>�C��|��_����*��?���N��II�� -�Ph���\kO.�x?6+��DB
citybuzz : Charlotte Raleigh : ArunA Bio Appoints Tony Townley to Board of Directors Charlotte Raleigh Search Share Your News ArunA Bio Appoints Tony Townley to Board of Directors 8/8/19 Tony Townley ATHENS, Ga. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )-- ArunA Bio, Inc. , a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced the addition of Tony Townley to its Board of Directors. A long-time entrepreneur and financier, Mr. Townley has overseen financial strategy and operations of fast-growing enterprises for over 30 years.
Aruna Bio Profile --> --> Sign In Tools to Win. Insights to Lead. Powerful Market Intelligence Leading Business Development Tools Authoritative Capital Markets Let's keep this going You've used all of your free views Free Trial Schedule Demo Free Trial Schedule Demo Description Search HigherGov Federal State | Local EXPLORE Search All BUSINESS DEVELOPMENT Opportunities Contracts Grants Pursuit Management Pipelines   +   Pursuits   +   Activities   +   Partner Finder Government Buyers Labor Pricing MARKET INTELLIGENCE Analysis Awards Vehicles Contracts Grants Award … nts Awardees Government Agencies People Documents Reference Programs Defense IT Grant SEWP Classifications NAICS NIA NSN PSC DoD Budget Protests Capital Markets M&A Transactions Investors Advisors TOOLS Downloads Favorites Saved Searches FOIA News+ Help Docs Federal State | Local BUSINESS DEVELOPMENT Opportunities Contracts Pursuit Management Pipelines   +   Pursuits   +   Activities   +   Government Buyers Labor Pricing MARKET INTELLIGENC … s Favorites FOIA Saved Searches Help Docs More SOLUTIONS FOR Contractors Grant Recipients Consultants Investors and Banks Government Agencies FEATURES Market Intelligence CRM Capital Markets Big Data & AI LEARN MORE Pricing Plans Demo Sign In Free Trial Notify New Contract Awards New Grant Awards Favorite Export Toggle Dropdown CSV Excel Claim Share Toggle Dropdown Copy URL Email Tweet Search Awardees Aruna Bio UEI: ND2FX8DQ2K33 • CAGE: 452D5 • DBA: ARUNA B … bsite http://www.arunabio.com Headquarters Athens, GA United States Most Recent Award Aug. 15, 2025 Calculating Show Quick Stats (See Federal Award Analysis for Full Details) Federal contract and grant recipient ARUNA BIO, INC. dba ARUNA BIOMEDICAL INC (UEI ND2FX8DQ2K33, CAGE 452D5) is headquartered in Athens GA. Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology). The corporation was founded in August 2003 and federally … was founded in August 2003 and federally registered in September 2005 . Federal Award Analysis Scope: Data includes non-classified prime contracts and grants reported by the government and subcontracts and subgrants as reported by prime awardees. Adjustments are made to aggregate related awardees, remove likely erroneous data, and to assign class
September 2018 Features - Athens CEO About Direct Connect Newsletter Contact Sponsor News Features Video Direct Connect Dilbert goBeyondProfit Local Communities Albany Atlanta Augusta Columbus Gainesville LaGrange Middle Georgia Newnan Rome Savannah Tifton Valdosta September 2018 Features Athens-based ArunA Bio Raises $5.3M to Fuel Growth & Innovation September 28, 2018 ArunA Bio announced that it has s … he garden. Piedmont Healthcare Now Accepting Applications for Community Benefit Grant Program September 25, 2018 Piedmont Healthcare’s community benefit grant program, which aims to improve the health and well-being of the community through direct service grants, is now accepting grants through October 12th. In Fiscal Year 2018, Piedmont provided an estimated $141 million in charity care. Labor Commissioner Butler to Host Employer Summit in Athens on October 3rd September 24, … ed the Georgia Chamber of Commerce the 2018 State Chamber of Year at its annual award ceremony held in New Orleans, Louisiana. Georgia Chamber Announces the Launch of the Georgia Screen Entertainment Coalition September 13, 2018 The Georgia Chamber of Commerce announced the launch of the Georgia Screen Entertainment Coalition, a statewide advocacy group focused on ensuring the long-term viability and success of Georgia’s screen entertainment industry. Local Chambers Partner t … he 39-mile walking, running and cycling path. Leadership Georgia Announces 2018 Award Winners September 06, 2018 The Leadership Georgia Board of Trustees is pleased to announce recipients of three coveted awards to be presented at this year’s annual gala. Leadership Georgia’s Annual Gala and Awards Presentation has become a signature event for honoring and celebrating the outstanding accomplishments and contributions that have been made by alumni and others to Leadership Geor … ontact / Sponsor / Newsletter Sections News / Features / Video / Direct Connect Submit Feedback / Press Releases & News Connect Twitter / Facebook Copyright © 2026 Athens CEO. All rights reserved. Terms & Privacy .
Aruna BIO Announces Appointment of Lynn Swann to its Board --> Accessibility: Skip TopNav Aruna BIO Announces Appointment of Lynn Swann to its Board of Directors June 03, 2024 07:00 ET | Source: Aruna Bio Aruna Bio BOSTON and ATHENS, Ga., June 03, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced the appointment of Lynn Swann to its Board of Directors. “It is a pleasure to welcome Lynn, a former NFL player, Hall of Famer, broadcaster, politician and athletic director, to our Board of
Exosome Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Exosome Therapeutics, Inc. Private Company | United States Private Company | United States Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Exosome Therapeutics, Inc. Login to view more data 0 Patents (Medical) associated with Exosome Therapeutics, Inc. Login to view more data 3 News (Medical) associated with … “a leg up,” she told BioSpace. The team also filed the Investigational New Drug Application and other regulatory forms themselves, which Stice noted gave them a clear understanding of the process. Manufacturing Exosomes at Scale Aruna Bio makes its exosomes in an in-house cGMP facility, which was “designed for flexibility,” Stice said. The adaptable nature of the facility allows the team to keep a close eye on the process and tweak the protocols when needed, which Stice said … a leg up,” she told BioSpace . The team also filed the Investigational New Drug Application and other regulatory forms themselves, which Stice noted gave them a clear understanding of the process. Manufacturing Exosomes at Scale Aruna Bio makes its exosomes in an in-house cGMP facility, which was “designed for flexibility,” Stice said. The adaptable nature of the facility allows the team to keep a close eye on the process and tweak the protocols when needed, which Stice said … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Aruna Bio - Privacy Policy Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Privacy policy Welcome to the web site (“Site”) of Aruna Bio (“Aruna Bio”, “Company”, “we”, “us” and/or “our”). This Site is operated by Aruna Bio and has been created to provide information about our company to our site visitors. This Privacy Policy sets forth Aruna Bio’s policy with respect to information including personally identifiable data (“Personal Data … e able to use certain Company Services. Exclusions This Privacy Policy does not apply to any Personal Data collected by Aruna Bio other than Personal Data collected through the Site. This Privacy Policy shall not apply to any unsolicited information you provide to Aruna Bio through this Site or through any other means. This includes, but is not limited to, information posted to any public areas of the Site, such as bulletin boards (collectively, “Public Areas”), any ideas for … rom children under the age of 13. If you are under the age of 13, please do not submit any Personal Data through the Site. We encourage parents and legal guardians to monitor their children’s Internet usage and to help enforce our Privacy Policy by instructing their children never to provide Personal Data on this Site without their permission. If you have reason to believe that a child under the age of 13 has provided Personal Data to Aruna Bio through this Site, please conta … na Bio (“External Sites”). The policies and procedures we described here do not apply to External Sites. The links from this Site do not imply that Aruna Bio endorses or has reviewed External Sites. We suggest contacting those sites directly for information on their privacy policies. Social Media Through the Site, you can choose to access certain social media websites and services that are owned and/or controlled by third parties (including, without limitation, Facebook and T
Aruna Bio - Presentation Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Please enjoy our latest corporate presentation If the presentation does not load in the window above, please click here . Contact us to discover more CONTACT US Financial Conflict of Interest in Research Policy Privacy Terms & Conditions Copyright © 2024 Aruna Bio, Inc. All rights reserved.
ArunA Bio Appoints Tony Townley to Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases Al … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals ArunA Bio Appoints Tony Townley to Board of Directors August 8, 2019 | 2 min read Twitter LinkedIn Facebook Email Print ArunA Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, announced the addition of Tony Townley to its Board of Director … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aruna Bio - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners T … clusters of differentiation stem cells transcription factors View Patents Chart Application Date Grant Date Title Related Topics Status 4/23/2021 11/12/2024 Neural cell extracellular vesicles Transcription factors, Clusters of differentiation, Stem cells, Proteins, Neurotrauma Grant Application Date 4/23/2021 Grant Date 11/12/2024 Title Neural cell extracellular vesicles Related Topics Transcription factors, Clusters of differentiation, Stem cells, Proteins, Neurotrauma Statu … factors, Clusters of differentiation, Stem cells, Proteins, Neurotrauma Status Grant Learn more by requesting a demo Latest Aruna Bio News Exosome Research Market Size to Reach USD 961.41 Million by 2034 Nov 3, 2025 USD 961.41 million by 2034, growing at a compound annual growth rate (CAGR) of 17.47% over the forecast period from 2025 to 2034. Ottawa, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The global was valued at USD 192.15 billion in 2024 and is anticipated to reach around USD … pected to grow at the fastest CAGR in the market during the forecast period. By application, the cancer research segment led the market with the largest revenue share in 2024. By application, the drug delivery systems segment is expected to grow at the fastest CAGR in the market during the forecast period. By workflow, the isolation segment held the highest market share in 2024. By workflow, the microfluidics-based isolation segment is expected to grow at the fastest CAGR in … tive landscape, growth factors, and trends Segments covered By Product Type, By Application, By Workflow, By End User, By Region Regional scope North America; Europe; Asia Pacific; Latin America; MEA Country scope U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailan
Aruna Bio Appoints Mike Ryan to its Board of Directors | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real Estate
Exosome Research Market Projected to Reach US$ 2,491.42 --> Accessibility: Skip TopNav Exosome Research Market Projected to Reach US$ 2,491.42 Million by 2035, Supported by Expanding Therapeutic Development Pipelines | Astute Analytica Validated clinical efficacy and scalable manufacturing propel exosomes from research discovery to commercial therapeutics. Regulatory clarity accelerates adoption, positioning exosomes as transformative platforms in diagnostics and drug delivery for global market expansion. January 13, 2026 12:30 ET | Source: AstuteAnalytica India Pvt. Ltd. AstuteAnalytic … utical industry captures 53% share through strategic manufacturing alliances By application, biomarker applications project to capture over 49.40% market share. North America is holding the market dominance with over 53.10% market share. By Products and Services, Kits and Reagents Sector Commands 56% Revenue Share via Next-Generation Hybrid Isolation Tools The trajectory of the exosome research market in 2025 is defined by a critical demand for ultra-pure yield, securing the … l factor for downstream multi-omics analysis. Major suppliers have responded by rolling out "workflow-agnostic" kits compatible with mass spectrometry and next-generation sequencing platforms. In 2025, sales of these integrated profiling kits surged, driven by a 35% increase in demand for standardized protocols that function across diverse biofluids, including saliva and urine. Furthermore, the commercialization of lyophilized (freeze-dried) exosome standards has revolutioniz … , necessitating industrial-grade purity that only the pharmaceutical sector can fund. This massive capital injection into large-scale production technologies has outpaced academic spending, cementing the commercial sector's dominance. By Application, Drug Delivery Applications Project 41% CAGR Driven by Blood-Brain Barrier Breakthroughs While biomarkers control the largest 49.40% of the exosome research market, the drug delivery application segment is the fastest-growing fron … ed for specific tissue homing, positioning drug delivery as the most high-value application for future revenue generation. Late Stage Trial Volumes Force Immediate Expansion Of Upstream Research Supply Chains Demand within the exosome research market is surging because therapy developers are transitioning from small safety cohorts to massive Phas
Aruna Bio - AB126 at Work Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact The Problem One of the biggest hurdles scientists and drug developers face is being able to deliver effective treatments to the brain in sufficient quantities to have a meaningful clinical effect. Crossing the blood-brain barrier requires significant advancement in order to make progress in the treatment of these devastating diseases. AB126 is the solution Aru
Aruna BIO Appoints Lynn Swann to Board Products Data Feature Plans Request Demo Sign Up for Free Aruna BIO Appoints Lynn Swann to Board 13 June 2024 Aruna Bio, Inc. , a leading company in the field of neural exosome-based therapeutics for neurodegenerative diseases, has announced a new addition to its Board of Directors. Lynn Swann, a former NFL player and Hall of Famer, has joined the board, bringing with him a wealth of experience from his diverse career as a broadcaster, politician, and athletic director. Bill Griffin, the Chairman of the Board at Aruna Bio, expressed his excitement about S
Aruna Bio Appoints John Richard to Board of Directors Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Stock Market & Corporate Newsroom | Real-Time Updates | CEO.CA Menu CEO.CA Watchlist Companies News Community SEDAR Research SEDI Insiders Private placements Contests Video Shop What's New? Sign Up Log In Articles # channel Loading... CEO.CA Chairman's Briefing Global Markets. Mining Trends. Every Thursday. Subscribe read first Please read the CEO.CA House Rules before posting. social Youtube Twitter Facebook Linkedin Instagram legal Use of this site indicates acceptance of the Privacy Policy and Terms of Use . The information on this Website is not reliable and not intended to p
Daily decarbonization news | decarbonfuse.com decarbonfuse Icons/logo toggle#toggle touch->toggle#toggle"> menu-alt-3 Icons/search Past issues ProjectDB dropdown#toggle click@window->dropdown#hide touch->dropdown#toggle touch@window->dropdown#hide" role="button" class="text-neutral-700 hover:text-neutral font-medium lg:px-3 py-2 lg:hover:bg-white rounded hover:text-emerald-700 transition ease-in-out duration-300 flex items-center lg:focus:bg-white focus:ring-4 focus:emerald-500/10" aria-label="More links"> More Icons/cheveron down Companies Press Releases & Announcements Sign in Join Pro A … micals • Published on November 3, 2022 C3 AI (NYSE: AI), the Enterprise AI application software company, today announced that seven new members will join the Open AI Energy Initiative (OAI), an open ecosystem of AI-based solutions for the energy and process industries. Ali... Press Release Produced Water Treatment Market 2023-2027: Increasing global concerns regarding water scarcity to drive growth- Technavio NEW YORK , May 9, 2023 /PRNewswire/ -- The produced water trea … ore Visitor Bureau Celebrates National Travel and Tourism Week with Program and Award Winners Port Orange Mayor Donald O Burnette receives Tourism Champion Award with Betsy Baker and Debbie Meihls 'We are so fortunate to enjoy incredible support from the hospitality and tourism businesses and professionals in our a... Read more Paris Baguette Continues To Dominate the Bakery Franchise Industry, Signs Agreement in Maple Grove, Minnesota to Mark Entrance Into The State MAPL … fter a remarkable 202... Read more RX3 Growth Partners Announces Oversubscribed Fund II Close Consumer Growth Equity Firm, Co-Founded by Aaron Rodgers , Expands Its Platform and Adds Additional Celebrity Investors ORANGE COUNTY, Calif. , May 9, 2023 /PRNewswire/ -- RX3 Growth Part... Read more Famous Dave's Announces Nationwide All-Star BBQ Championship Series in Partnership with the World Food Championships (WFC) MINNETONKA, Minn. (PRWEB) May 09, 2023 Barbeque enthusiast … Healthcare, and Hawaiian Electric: Johnson Fistel, LLP Encourages Investors to Submit Their Information Below SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of (NYSE: DG) against certain of its officers and directors. If you are a current, long-term sharehold... Read more Electrical C
Aruna Bio | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Aruna Bio Website: Aruna Bio Business Area(s) Stem Cells Exosomes Neurological Disease Description Auruna Bio is developing treatments for neurodegenerative disorders that use neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechani
Aruna Bio - Careers Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Careers At Aruna Bio, we seek to transform patients lives by harnessing the untapped potential of exosomes to address a large number of diseases and disorders. Dedicated Impacting patient outcomes is what drives us Passionate For science, our colleagues and mission Determined Improvement requires challenge Joining Aruna Bio offers the ability to be part of an engaged, … We are currently seeking to fill the following position(s): No items found. To apply for any of these positions, please submit your resume and cover letter to [email protected]. Aruna Bio is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person’s race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristi
%PDF-1.4 %���� 6811 0 obj > endobj xref 6811 136 0000000016 00000 n 0000006755 00000 n 0000006941 00000 n 0000011307 00000 n 0000011852 00000 n 0000012444 00000 n 0000012559 00000 n 0000013073 00000 n 0000013677 00000 n 0000013790 00000 n 0000014041 00000 n 0000014645 00000 n 0000016711 00000 n 0000017392 00000 n 0000017692 00000 n 0000018061 00000 n 0000018186 00000 n 0000018461 00000 n 0000019095 00000 n 0000019366 00000 n 0000019626 00000 n 0000021224 00000 n 0000024266 00000 n 0000027227 00000 n 0000030140 00000 n 0000033100 00000 n 0000035649 00000 n 0000038165 00000 n 0000041853 00000 n … �{ ���t;�������}�F_�XꝽ3V���79�J��l�j"�r�X���[j*OU����R"G���Z)�S���� >stream application/pdf RESI Full 2022-08-30T13:23:11-04:00 2022-08-30T13:23:11-04:00 2022-08-30T13:23:10-04:00 Adobe Illustrator 26.3 (Windows) uuid:166d2bf4-d4d5-4dba-af2c-9687b1393474 xmp.did:b8b627b9-63dc-f348-9625-1ed948e71f30 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:40f0d353-75a6-694e-b6ea-5f797d1823ba xmp.did:40f0d353-75a6-694e-b6ea-5f797d1823ba uuid:5D20892493BFDB11914A8590D31508C8 … Adobe PDF library 16.07 endstream endobj 6844 0 obj > endobj 6845 0 obj >stream application/pdf LSN Logo 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 Adobe Illustrator 26.3 (Windows) uuid:4f5ba327-632d-4d3e-9750-3dbb5ac53375 xmp.did:08a59ab9-3855-0341-99ff-96f16744b3b7 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:b8b627b9-63dc-f348-9625-1ed948e71f30 xmp.did:b8b627b9-63dc-f348-9625-1ed948e71f30 uuid:5D20892493BFDB11914A8590D31508C8 d … Adobe PDF library 16.07 endstream endobj 6846 0 obj > endobj 6847 0 obj >stream application/postscript Print yang zhou 2024-02-29T13:22:42-05:00 2024-02-29T13:22:42-05:00 2024-02-29T13:22:42-05:00 Adobe Illustrator 28.2 (Windows) xmp.iid:c50db9cd-003f-9945-b46b-ef5e016e0181 xmp.did:c50db9cd-003f-9945-b46b-ef5e016e0181 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:c9914b06-205d-4060-b620-fae57f2f5102 xmp.did:526773d2-a98f-654f-bf01-cbbe9b3a6f9d uuid:5D20892493BFDB11914A … Adobe PDF library 15.00 endstream endobj 6848 0 obj > endobj 6849 0 obj >stream application/pdf mwe logo 2022-08-30T13:43:32-04:00 2022-08-30T13:43:32-04:00 2022-08-30T13:43:32-04:00 Adobe Illustrator 26.3 (Windows) uuid:0ecfffc3-c2cf-4889-a794-845a42faa9be xmp.did:642af632-b2e8-b347-bd6b-8d744cc5b988 uuid:5D20892493BFDB11914A8590D31508C8 proof:p
Aruna Bio Jobs | BioBae Bio Bae Browse Jobs Companies For Employers Home / Companies / Aruna Bio A Aruna Bio Biotechnology 📍 Athens , GA Aruna Bio develops proprietary neural exosome therapeutics for CNS diseases like stroke and Alzheimer's, overcoming the blood-brain barrier. Visit website → View careers page → Open Positions at Aruna Bio 0 positions available No open positions at the moment Check back later for new opportunities! Bio Bae The premier job board for biotech, pharma, and life sciences professionals. For Job Seekers Browse Jobs Remote Jobs Companies For Employers Post a Job
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Establishment of Transgenic Induced Immortal Chicken Cell Line The latest Aruna Bio updates and events Financial Conflict of Interest in Research Policy Privacy Terms & Conditions Copyright © 2024 Aruna Bio, Inc. All rights reserved.
%PDF-1.6 %���� 41840 0 obj > endobj 41863 0 obj >/Filter/FlateDecode/ID[ ]/Index[41840 36]/Info 41839 0 R/Length 115/Prev 2042475/Root 41841 0 R/Size 41876/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� �@$S5XDD2���`Y�} �� ��b��'����jԀ$��p�H+� b�7�H G�� R� lr"HMH�߳ L� ���]��H&��!~�7���c endstream endobj startxref 0 %%EOF 41875 0 obj >stream h�b```�� �@җA���X��c���T&��i�� aN�~(Gr `J �Y#��ÈI�`��r� �_@���z�&��8�B�;����hrT6�L����SBo��CNw���&�H�(�x��"*8ÙLz�q�� �{0�E��!&_�Y/��r w�}лG�%g�S�@��^�EL� �ETVp� >/Metadata 673 0 R/PageLayout/OneColumn/Pages 41807 0 R/StructTreeR … �l\�Y_K���S�� �r+�'5`E�i�}Vt�j���9 ��93���-�*����rN�E�)&���tl�`w��9qlx���$rfP���^����|�}� ��>� �3�dž��$��30��\'�ze=W���(�OF�/��c��q s���?g,ɟ��E�g�L18�(����8&pvd��cN ^;���O� y�N`�bpRXt %݇E�QL�̼�3t��8C��O�yJ&0s�����(�>,��� Lw��Ӝ���I��yJ&0s����0�>*�� ���9� ̜�$r���c2�����݇I�q�}pL�;o�� ��͒7��1w͟�����b@RRt $�'E��1�o���4'�7��$rF{�O&�s����F�}Rt�8&�7���2do`�I�����j�] endstream endobj 529 0 obj >stream hތW��\7 }/�E�X�!PH��R>�� �tQ��T����j�l … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:d5c954ed-4e63-4120-9c4e-4fee49bb2d27 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 674 0 obj >stream hޜ��n1�_��`�����\8r�"n�C$"� � �U���ha|����s��*w����]��M��7�A,A��CY��\RC5J�XM�96KI��H���J3|��� U-tY}H��i��Ӑ.�i �(� �D�aX�a�e�� �ˆ)�ley���8���4fsS ���,�G1���$u��?�F9���>���8��������_�^{�zz����G,m�G�U����T���>�>���|zx���r��� … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:197d980b-d491-4ad6-9ce6-c98f78fcfff2 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 41842 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 41876 0 obj > endobj 41877 0 obj >stream H���mo����S�B �VK.�@� ���; ���"+���JJ.�� �W�Ȍ�&H$�,9�?��ο� 6���C������a��Y_ ��C����l���P� �����jQ� … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:38a70a0c-3e84-4398-a1b1-6e1d89d8496a 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 41842 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 41887 0 obj > endob
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
Welcome to the 7th Exosome-Based Therapeutic Development Summit | pharmaphorum Skip to main content Thursday 25 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research
Scientific Program - NNS 2026 Skip to content NNS 2026 #NNS2026 Facebook X-twitter Linkedin Menu Home General Info Welcome Message Venue Information Onsite Information City Information Important Dates NNS Advocacy Public Forum Program Planning Committee Program At A Glance Speaker Resources Scientific Program Confirmed Speakers Top 20 Posters Travel Awards CME Information Registration Registration Accommodation Sponsorship & Exhibits Confirmed Sponsors & Exhibitors Sponsorship & Exhibit Opportunities Exhibitor Manual Promo Kit Contacts Scientific Program Scientific Program Detail … itment/retainment -Our work to support researchers through state-level research grant bills, including our current effort in WI. -Our work to defend research investment at the Federal level: the fight to save DOD SCIRP and the broader CDMRP -A call to rethink urgency, incentives and organization and coordination of siloed research toward a functional recovery endpoint. 12:00 am - 12:00 am KN01 - Session Chair Gene Gurkoff, Dr. Professor University … Boston University Kaelin Sbrocco, Ms. 1:40 am - 1:43 am DB01.11 - Retrospective Application of the 2023 American Congress of Rehabilitation Medicine’s Diagnostic Criteria for Mild Traumatic Brain Injury Laura McGuigan, Ms. Graduate Student Medical College of Wisconsin Laura McGuigan, Ms. 1:43 pm - 1:46 pm DB01.12 - Effects of Transcranial Magnetic Stimulation on Sleep and Astrogliosis Following Repetitive Traumatic Brain Injury Nija White, Ms. Phd Candidate Florida Internatio … women with mTBI. At the conclusion of this symposium, attendees will be able to apply the information to inform an evidence-based, multidomain assessment and targeted treatment approach to women with mTBI. Attendees will also have a better understanding of the neurobiological effects of mTBI on mechanistic pathways related to women’s health outcomes following mTBI. 2:45 pm - 2:55 pm S01 - Chair Anthony Kontos, Dr. Professor/vice Chair Of Clinical Research University Of … on Description: The proposed symposium will feature presentations on real-world application of the new CBI-M framework from the National Institutes of Neurologic Disorders and Stroke (NINDS) for characterization of acute traumatic brain injury (TBI). The CBI-M model is the resultant of a NINDS-sponsored, consensus-driven process that involv
Aruna Bio - Careers Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Careers At Aruna Bio, we seek to transform patients lives by harnessing the untapped potential of exosomes to address a large number of diseases and disorders. Dedicated Impacting patient outcomes is what drives us Passionate For science, our colleagues and mission Determined Improvement requires challenge Joining Aruna Bio offers the ability to be part of an engaged, … We are currently seeking to fill the following position(s): No items found. To apply for any of these positions, please submit your resume and cover letter to [email protected]. Aruna Bio is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person’s race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristi
Aruna Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Healthcare Life Sciences & MedTech Summit - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FD … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Bio NC Aruna Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Healthcare Life Sciences & MedTech Summit September 8, 2021 | 2 min read Twitter LinkedIn Facebook Email Print Aruna Bio, Inc. today announced that Dr. Mark A. Sirgo , Chief Executive Officer, will be pres … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
New Events — MSQ MSQ Home About Healthcare Events Client Testimonials Contact Back About Us MSQ Team Advisory Team Network Back MSQ Viewpoints MSQ Webinar Back New Events Past Events Home About About Us MSQ Team Advisory Team Network Healthcare MSQ Viewpoints MSQ Webinar Events New Events Past Events Client Testimonials Contact MSQ Ventures Apr 27 4:30 PM 16:30 Powering Drug Development with US – China Collaboration - Biocom Reception Monday, April 27, 2026 4:30 PM 7:00 PM 16:30 19:00 Jones Day Office (map) Google Calendar ICS Powering Drug Development with US – China Collaboration … nk below. Capacity is limited and registrations will be reviewed on a rolling basis, early registration is encouraged. We look forward to seeing you in Shanghai. Scan to register to the event! View Event → Jan 11 12:30 PM 12:30 2026 Global Biopharma Leadership Forum Sunday, January 11, 2026 12:30 PM 6:30 PM 12:30 18:30 San Francisco, CA (map) Google Calendar ICS On Sunday, January 11, 2026, senior leaders from across global biopharma will gather at the J … ers, Jones Day 11:30AM -12:10PM: Fireside Chat with Les Funtleyder Fund Manager and Interim CEO, CFO, Member, Board of Directors, Applied Therapeutics & Kimberly Ha , Founder & CEO of KKH Advisors 12:10 – 12:30 PM: Closing Remarks 12:30 – 1:00 PM: Networking Lunch & Open Discussion Session Speakers This workshop centers on practical learning and real discussion. Through immersive case studies and expert-led conversations, participant … rtant partnerships with a Big Pharma and other development organizations. Multi-award-winning Biotech CEO, having received amongst others the Swiss Technology Award 2011, Venture Kick 2009 and Venture Leaders 2008 and 2017 awards for his work in founding and advancing BioVersys. He is also President of the Board of the BEAM Alliance, a European association representing over 70 European and international SMEs active in antimicrobial research and development and Board member of … ingapore Immunology Network from 2008 to 2010. Her accolades include the Domagk award, the Kennedy Visiting Professorship Award, and the Scientist of the Year Award in 2014. Svanborg's prolific contributions are evident in her 400+ published papers, and she has mentored numerous graduate students and postdoctoral fellows, many of whom have gone o
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Aruna Bio to Participate in Upcoming Investor Conferences - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Release … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Aruna Bio to Participate in Upcoming Investor Conferences March 18, 2024 | 1 min read Twitter LinkedIn Facebook Email Print Aruna Bio, Inc. today announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at upcoming investor conferences. BOSTON and ATHENS, Ga., M … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
--> EVFL2024 | Select Biosciences top of page 2026 Conferences At-a-Glance Microfluidics Shenzhen Jan2026 Exosomes Shenzhen Jan2026 Exosomes-EV Portland March 2026 Next-Gen EV Instruments & Tools Denver Flow Chemistry Asia Shenzhen June2026 Microfluidics, EVs, LNPs Europe 2026 Microfluidics, Organs-on-Chips, Dx Japan Lipid Nanoparticles (LNPs) Japan 2026 Extracellular Vesicles (EV) Japan 2026 Space Summit Asia-Pacific-Japan 2026 Lab-on-a-Chip & Microfluidics - Oct2026 EVs and LNPs Laguna Hills - Oct2026 Space Summit West - Oct2026 Exosomes-EVs Kuala Lumpur - Dec2026 Point-of-Care & … and Pharmaceutical Sciences, United States of America Amber Murray, Senior VP, Application, Exokeryx Clayton Deighan, North American Sales and Applications Manager, NanoFCM Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS) Eun Ji Chung, Dr. Karl Jacob Jr. and Karl Jacob III Early Career Chair, University of Southern California, United States of America Giacomo Vacca, President & CEO, Kinetic Riv … a Giacomo Vacca, President & CEO, Kinetic River Corp Johnny Zhuang, Product Application Scientist, EXODUS BIO Mei He, Associate Professor, University of Florida, United States of America -- Conference Co-Chair Raymond Schiffelers, Professor of Nanomedicine, University Medical Center Utrecht, The Netherlands Sukhbir Kaur, Staff Scientist, National Cancer Institute, National Institutes of Health Andrea Raymond, Associate Professor, Herbert Wertheim College of Medicine, Flor … ics You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now! Poster Submission Deadline: 1 April 2024 • Biomarker Content of Extracellular Vesicles and Role for Diagnostics • Disease Areas where EV-based Diagnostics Being Developed • Extracellular Vesicles (EVs): Therapeutic and Drug Delivery Potential • Single Extracellular Vesicle (EV) Analysis by Flow Cytometry • Technologies for Engineering EVs for Therapeutics, … 2024: Diagnostics, Delivery, Therapeutics Training Courses If you would like to submit a proposal for an oral or poster presentation at this meeting, please fill out the form below required for your submission. Successful applicants will be provided with all necessary information. Abstract Content: W ritten in English Written in the thir
BioProcess | FOCUS Event Series You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Highly Focused Topics Delivered in a Digital Format Submerge Yourself in Content Driven Discussions Home home Portfolios expand_more Antibody BioProcess Clinical Medical Devices T
Trial to be Launched for Ischemic Stroke Cell Therapy - RegMedNet Skip to main content RegMedNet is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Our journals Our journals Journal content Journal articles Follow us on social media Topics CAR-T Stem cells Cell therapy Gene therapy Gene editing Cancer
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication Home Membership Become a Member Cost-Savings Program Councils and Networks Advocacy Legislative Watch 2026 Take Action Legislative Engagement Events Day at the Capitol Patient Advocacy Georgia Rare Disease Advisory Council (RDAC) Patient's Corner Resources & Articles Programs Workforce Pipeline Biotech Teacher Training Initiative Equipment Depot Career Network Ambassadors Program Emerging Leaders Network BioGENEius Challenge Customized … od and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of lead program, AB126. This decision paves the way for the Phase 1b/2a clinical trial in acute ischemic stroke, which is expected to initiate in the first half of 2024. AB126 is an unmodified neural-derived exosome with an innate ability to traverse the blood brain barrier and shows evidence of anti-inflammatory and neuroprotective properties. “We are thrilled with this validati … agencies to adopt clear, workable and predictable standards that companies can apply with confidence. That includes preserving enforcement safety zones for low-risk, pro-competitive collaborations, as well as ensuring the HSR Form facilitates a timely, focused and fit-for-purpose screening process for life sciences M&A deals. Click below to read PULSE’s full comments: PULSE Comments on Guidelines on Collaborations Among Competitors PULSE Comments on Improvements to
Aruna Bio - Publications Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Publications Filter by: All Exosomes Model Development Stem Cells April 28, 2026 Translational Stroke Research Serum Neurofilament Light Chain Predicts Stroke Outcome and is a Potential Marker for Treatment Effects of Neural Stem Cell-derived Extracellular Vesicles in a Rat Stroke Model March 14, 2026 Journal of Neuro-Oncology Disrupting Akt-Wnt/β-Catenin Signali
Aruna Bio - Financial Conflict of Interest in Research Policy Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Financial Conflict of Interest in Research Policy The following Financial Conflict of Interest (FCOI) Policy is specific to all government sponsored grants or government funded contracts. This Policy is intended to ensure compliance with 42 CFR 50, Subpart F, "Responsibility of Applicants for Promoting Objectivity in Rese … ticipating in such government funded research; provided, however, this does not apply to SBIR Program Phase I applications. If a research project involves subcontractors, subgrantees, or subawardees (collectively subrecipients), the subrecipient institution must provide written assurance that a financial conflict of interest in research policy is in effect at that institution and compliant with all applicable federal regulations. Should Public Health Service (PHS) or National … erest in research policy, a written agreement must state that this policy shall apply to the subrecipient. 3.Definitions. 3.1. Contractor means an entity that provides property or services under contract for the direct benefit or use of the Federal Government. 3.2. Disclosure of significant financial interests means an Investigator's disclosure of significant financial interests to Aruna Bio. 3.3. Financial conflict of interest (FCOI) means a significant financial inte … or private, entity or organization (excluding a Federal agency) that submits a proposal, or that receives, PHS research funding. For the purposes of this policy, Aruna Bio is considered Aruna Bio. 3.8. Institutional responsibilities are an Investigator's professional responsibilities on behalf of Aruna Bio, and as defined by Aruna Bio in its policy on financial conflicts of interest, which may include for example: activities such as research, research consultation, teac … e with HHS requirements and who are identified as key personnel in the contract proposal and contract. 3.11. Manage means taking action to address a financial conflict of interest, which can include reducing or eliminating the financial conflict of interest, to ensure, to the extent possible, that the design, conduct, and reporting of research wi
Aruna Bio | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Aruna Bio Aruna Bio is dedicated to transforming the treatment of neurodegenerative and neurological diseases by developing innovative neural exosome platforms. With a focus on crossing the blood-brain barrier, their proprietary neural exosomes, such as AB126, demonstrate potential to reduce neuro-inflammation, promote neuroprotection, and stimulate neuro-regeneration. Their mission is to bring new hope to millions affected by these challenging conditions through sca
Aruna Bio, Inc. - BIO Investor Forum | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membership Options Be
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Steven Stice, PhD Co-Founder, Chief Scientific Officer Dr. Steve Stice is the Chief Scientific Officer of Aruna Bio In this role, he directs the company’s research operations. He is also a University of Georgia DW Brooks Distinguished Professor and the Director of the Regenerative Bioscience Center. Steve holds a Georgia Research Alliance Eminent Scholar endowed chair. Prior to
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Aruna Bio - Executive Leadership Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact The Management Team Mike Ryan Chief Executive Officer • 25 Years of Biotech Management and Finance Experience • Served over a decade as CEO at the companies Artema and Sedana Medical • Founder-Director of Irrus Investments – the largest angel investment syndicate in Ireland Steven Stice, PhD Co-Founder, Chief Scientific Officer • Professor & Director,
Aruna Bio Announces Appointment of Mike Ryan to its Board --> Accessibility: Skip TopNav Aruna Bio Announces Appointment of Mike Ryan to its Board of Directors December 19, 2022 08:00 ET | Source: Aruna Bio Aruna Bio BOSTON and ATHENS, Ga., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced the appointment of Mike Ryan to its Board of Directors, effective immediately. Mr. Ryan brings valuable industry experience to the Company. "It is a pleasure to welcome Mi
Aruna Bio - Board of Directors Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Board of Directors C. William "Bill" Griffin Chairman of the Board Bill Griffin is Executive Vice President and Senior Managing Director of Fidelity National Financial. In this role, Bill helps lead Fidelity’s efforts to deliver its end-to-end solutions to the country’s largest financial institutions. Because of his leadership in and knowledge of
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Mike Ryan Chief Executive Officer Starting in 2005, Mike was a founder investor and board member of SedanaMedical, which was listed on the (NASDAQ) First North stock exchange in June 2017. He also served as the CEO of Sedana Medical from 2011 to 2017. The market capitalization of this company briefly exceeded $1 billion in 2020. Mr. Ryan was also the main shareholder and CEO of
Aruna Bio Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Tracey Worthington-Stice Co-Founder, Chief Operating Officer Tracey Worthington Stice is the Chief Operating Officer of Aruna Bio Under her direction, Aruna Bio was the first to company to commercialize a neural stem cell line derived from human pluripotent stem cells. Now, under her leadership in bio-processing, the company is prepared to model a new class of cell-free biologi
Aruna Bio - Stem Cell Publications Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact Publications Filter by: All Exosomes Model Development Stem Cells April 27, 2021 Scientific Reports Development of an Objective Index, Neural Activity Score (NAS), Reveals Neural Network Ontogeny and Treatment Effects on Microelectrode Arrays January 12, 2021 Frontiers in Neuroscience Electrophysiological Analysis of Brain Organoids: Current Approaches
Aruna Bio - Pipeline Home Our Company Mission Executive Leadership Board of Directors Stroke Advisory Board Platform Intro to AB126 AB126 at Work Pipeline News Press Releases Publications News Articles Presentation Careers Contact A Powerful CNS Therapeutic Pipeline Plans are already in place for an ambitious pipeline for our neural exosomes – across a broad range of indications. However, new indications will be added regularly to this pipeline as our horizons widen. Contact us to discover more CONTACT US Financial Conflict of Interest in Research Policy Privacy Terms & Conditions Copyrigh
Aruna Bio Home Our Company Platform Pipeline Our People News Careers Contact Unlocking new possibilities for millions with neurological disease By developing our own proprietary neural exosome platform, Aruna Bio has succeeded in gaining access across the blood-brain barrier. Our therapeutic neural cell-derived exosome, AB126, demonstrates multiple modes of action: reducing neuro-inflammation promoting neuro-protection stimulating neuro-regeneration This makes AB126 ideal for the treatment of acute neuro-conditions and chronic neurodegenerative diseases which could transform the lives of milli
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Steven Stice | Regenerative Bioscience Center University of Georgia Search Search for: Alumni & Giving News Academics Home About Us Leadership Our Experts A-Z Message from the RBC Director RBC Faculty Awards Join Us Stem Cell FAQs Research Research Interests Research News Research Events RBC Impact Research Funding Research Pilot Funding NIIMBL Seed Grant Opportunities Students Student Recruitment Graduate Program Graduate Group Meetings Undergraduate Program RBC Fellows Program Student Application Undergraduate Internships Undergraduate Student Stories Annual Symposium Spotlight on Studen … cently, Aruna Bio obtained FDA clearance for the Investigational New Drug (IND) application, marking the first U.S. clinical trial utilizing exosomes to treat acute ischemic stroke. Scheduled to commence in the first half of 2024, the trial is expected to begin in the middle of summer. Currently, the Stice lab is developing novel therapies and new technologies for drug screening and neurodegenerative disease, which could change the lives of those suffering with Parkinson’s, S … dent and pig models (2017) Aruna Bio cleared the Investigational New Drug (IND) application with the FDA to initiate the first U.S. clinical trial using exosomes to treat acute ischemic stroke (2023) Links Publications by Steven Stice may be found at Google Scholar . For more information visit the Stice Lab . Awards Alpha Zeta Honorary Nominated for Biotechnology’s Outstanding Young Researcher by Massachusetts Biotechnology Association member (Fienstein Kein Partners) i … iation member (Fienstein Kein Partners) in 1999. Nominated for Grand Presidents Award, Alpha Gamma Rho fraternity (1998). Georgia Research Alliance Eminent Scholar (1999) Membership in the Executive Round Table Leadership Society (1999) Top 40 entrepreneurs under 40 in the state of Georgia (Georgia Trends, 2000) Grand Presidents Award, Alpha Gamma Rho fraternity (2000). Outstanding Service to Young Scholars Research program (2000) Leadership in Agriculture award. College of A … ure award. College of Agriculture, University of Illinois (2001) AAAS stem cell grant reviewer (2001) Keynote speaker first Georgia Life Science Summit (2001) One of 100 most Influential Georgians (Georgia Trends, 2002) Chairmen of the GRA Applied Genomics Cluster (2002) Emtech Bio Scientific Advisory Board member(2002) Harold W. Gegenheimer Inno
Aruna Bio Announces Issuance Of A New Composition Of Matter Patent Covering Neural Exosomes In Japan | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Aruna Bio Announces Issuance of U.S. Patent for Composition of Matter for Neural Exosomes Used to Deliver Therapeutics to the Brain | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Aruna’s AB-126 cleared to enter clinic for acute ischemic stroke | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landsc … chemic stroke Jan. 17, 2024 Aruna Bio Inc. has gained FDA clearance for its IND application for AB-126, enabling initiation of a phase Ib/IIa trial in acute ischemic stroke. BioWorld Science Regulatory Neurology/psychiatric FDA IND Popular Stories Today's news in brief BioWorld BioWorld briefs for June 24, 2026. Have brain-computer interfaces finally arrived? BioWorld More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their head
#bio2024 | Aruna Bio, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip
Aruna Bio to Present at BIO International Convention 2024 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Release … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest Aruna Bio to Present at BIO International Convention 2024 May 28, 2024 | 1 min read Twitter LinkedIn Facebook Email Print Aruna Bio, Inc. announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at the 2024 BIO International Convention being held June 3-6, 202 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin